Skip to main content
Caplight Logo









Holiferm

Holiferm

Private
ManchesterFrontier & Industrial Techhttps://holiferm.com/

Last Round

Series B

Dec 6, 2023

Total Funding Raised

$34.27M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Holiferm is a biotechnology company that develops processes for and manufactures innovative, green and sustainable biosurfactants.

Sector

Frontier & Industrial Tech

Verticals

Biotechnology, Sustainable Materials, Clean Manufacturing

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

biosurfactantsrhamnolipidsgreen chemistrybiomanufacturingsustainable ingredientsfermentation technologycontract fermentationbio-based surfactantsclean label ingredientsindustrial biotechnologyspecialty chemicalsbio-economywhite biotechsustainable manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Holiferm Comparables

Compare Holiferm with similar companies based on industry and business-model similarity.

Holiferm comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Biotensidon GmbH
87%
AGAE Technologies
84%
AmphiStar
84%

Holiferm Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 6, 2023
VC RoundJul 31, 2023
Series ANov 12, 2021
GrantNov 9, 2020
SeedMay 1, 2019

Key People

Founding team and executive leadership

Ben Dolman

CIO And Founder

Founding Team

Charles Dimmler

Chief Executive Officer

Executive Team

Richard L.

Chief Operating Officer, Managing Director

Executive Team

Holiferm Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 70% MoM.

  • Jun 18, 2026

    Monthly visitors increased 112% MoM.

Recent news

Latest coverage and updates

  • is_developingSep 14, 2026

    Holiferm is developing novel performance biochemicals on Sep 8th '26.

  • acquiresSep 8, 2026

    Holiferm acquired Organica UK Ltd on Sep 8th '26.

Holiferm Filings

Explore SEC and related filing metadata, where available.

Holiferm filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Holiferm's valuation, stock price, and market status.

Is Holiferm a public or private company?

Holiferm is a private company.

What is the current stock price of Holiferm?

Holiferm is a private company with no public stock price. No recent secondary market data is available.

How much is Holiferm worth (valuation)?

Valuation information for Holiferm is not publicly available.

Can I buy Holiferm stock?

Holiferm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Holiferm's last funding round?

Holiferm's most recent funding round was Series B on December 6, 2023.

Who are the main investors in Holiferm?

Key investors in Holiferm include Rhapsody Venture Partners, Clean Growth Investment Management.

Will Holiferm IPO soon?

No public IPO plans have been announced for Holiferm.

How can I track Holiferm secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Holiferm's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersManchester
Employee Range58
Year Founded2018
Last FundingDec 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?